The majority of lung cancers (about 85%) are non-small cell lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) mutations are the most frequent driver mutation in lung cancer, occur in around 50% of Asia-Pacific patients with NSCLC and 15% of Western patients (2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.